MedTrace Logo

Effect of Statin Therapy on Sepsis-related Mortality in Intensive Care Unit Patients

NCT06354452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59578

Last updated 2024-04-09

No results posted yet for this study

Summary

The average age of patients with sepsis has increased in recent years in parallel with the incidence of sepsis. Many of these patients are frail and require various medications for the treatment of their chronic diseases. Common treatments, including e.g. sarcopenic drugs (statins, sulphonylureas, methyglinides), antioxidants that prevent sarcopenia (allopurinol) or immunoregulators (corticosteroids) may influence the survival and functional prognosis of these patients. Knowing which drugs influence sepsis survival and to what degree patients who survive sepsis have functional deterioration and increased comorbidity and which modifiable factors limit this may be essential.

Conditions

Interventions

OTHER

Person-level linkage of the database looking for relationship with sepsis survival and previous intake of certain drug families and previous dependence on health services.

A descriptive analysis of the baseline demographics, risk factors, health status, comorbidities, frailty, and previous dependence on health services of all patients admitted to hospitals in the region will be carried out. Both the overall data of patients admitted to hospitals in any ward and those admitted to ICU will be analysed. The survival data of patients will be compared with their previous individual drug consumption, trying to find out the relationship between chronic consumption of certain families of drugs and inhospital survival to sepsis. In addition, drug dependence and dependence on health services of sepsis survivors will be studied in comparison with their situation prior to sepsis.

Sponsors & Collaborators

  • Department of Health, Generalitat de Catalunya

    collaborator OTHER_GOV

  • Hospital de Granollers

    lead OTHER

Principal Investigators

  • Josep M Badia, MD, PhD · Hospital General de Granollers

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2019-12-31
Completion
2020-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06354452 on ClinicalTrials.gov